FindMyKOL
Clinical trialNCT06564571RecruitingObservational

Artificial Intelligence in Endoscopic Ultrasound

NCT06564571 is an observational study sponsored by Orlando Health, Inc.. As of 21 Nov 2026, it is recruiting participants. It studies Pancreas Disease, Pancreatic Cancer and 1 more condition. The registry lists an enrollment of 310 participants at 1 site in 1 country. The registry lists a start date of 19 Jan 2024 and a primary completion date of 31 Dec 2026.

SponsorOrlando Health, Inc.Enrollment310Pancreas DiseasePancreatic CancerPancreatic Cyst
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06564571
FieldValue
Registry IDNCT06564571
StatusRecruiting
Study typeObservational study
Lead sponsorOrlando Health, Inc.
Enrollment310
Registered sites1
Countries1
ConditionsPancreas Disease, Pancreatic Cancer and Pancreatic Cyst
Start19 Jan 2024
Primary completion31 Dec 2026
Study completion31 Dec 2027
Last update posted31 May 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site, 1 recruiting
  • Orlando Health

    Orlando

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 site, 1 recruitingFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT06564571

Each answer restates registry values shown on this page.

What is NCT06564571?

NCT06564571 is an observational study sponsored by Orlando Health, Inc.. It studies Pancreas Disease, Pancreatic Cancer and 1 more condition.

Is NCT06564571 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06564571?

The registry names Shyam Varadarajulu, MD (principal investigator, Orlando Health, Digestive Health Institute) as the overall official.

Where does NCT06564571 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT06564571 expected to complete?

The registry lists a primary completion date of 31 Dec 2026 and a study completion date of 31 Dec 2027. The sponsor last updated the record on 31 May 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.